12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights 59 minutes ago
Movers
Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 13.9% to $2.2 during Tuesday's after-market session. The company's market cap stands at $73.3 million. Longeveron (NASDAQ:LGVN) stock moved
Gainers
- Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 13.9% to $2.2 during Tuesday's after-market session. The company's market cap stands at $73.3 million.
- Longeveron (NASDAQ:LGVN) stock moved upwards by 5.3% to $2.99. The market value of their outstanding shares is at $6.4 million.
- Instinct Bio Technical Co (NASDAQ:BIOT) shares increased by 4.55% to $0.18. The company's market cap stands at $5.3 million.
- Firefly Neuroscience (NASDAQ:AIFF) stock rose 4.46% to $1.02. The company's market cap stands at $14.8 million.
- MaxCyte (NASDAQ:MXCT) shares moved upwards by 4.42% to $1.18. The market value of their outstanding shares is at $134.1 million. The company's, Q3 earnings came out today.
- NovoCure (NASDAQ:NVCR) shares increased by 4.06% to $12.29. The market value of their outstanding shares is at $1.4 billion.
Losers
- Stereotaxis (AMEX:STXS) stock fell 16.1% to $0.88 during Tuesday's after-market session. The company's market cap stands at $114.2 million. The company's, Q3 earnings came out today.
- Karyopharm Therapeutics (NASDAQ:KPTI) shares fell 10.92% to $0.02.
- Neuronetics (NASDAQ:STIM) stock decreased by 9.96% to $1.81. The market value of their outstanding shares is at $166.1 million. As per the news, the Q3 earnings report came out 4 days ago.
- Exicure (NASDAQ:XCUR) stock declined by 8.22% to $0.99. The company's market cap stands at $5.8 million.
- Mustang Bio (NASDAQ:MBIO) shares declined by 4.69% to $0.43. The market value of their outstanding shares is at $2.9 million.
- Skye Bioscience (NASDAQ:SKYE) stock fell 4.65% to $0.8. The market value of their outstanding shares is at $3.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
